Tralokinumab is a new drug for the treatment of atopic dermatitis.
Aim of the study
The aim of the study is to detect and quantify tralokinumab in the skin of treated patients with atopic dermatitis and simultaneously characterize the cellular and molecular changes of the cutaneous and systemic immune response under this therapy.
Who can take part?
Patients with moderately severe atopic dermatitis (neurodermatitis)
Healthy control subjects
Procedure
The study includes one visit for control subjects. During this visit, blood is taken as well as skin swabs and a small skin sample.
Patients with atopic dermatitis receive tralokinumab for 16 weeks in the study. After an initial examination, the medication is administered subcutaneously every two weeks. At the beginning of the therapy, after four, eight and 16 weeks, blood is taken, skin swabs are taken and a small skin sample is taken.
Compensation
None
Original study name
Effects of tralokinumab in the skin: an immunologic and molecular investigation
BASEC number
2022-01402
Financial support from